替比夫定治疗慢性乙型重型肝炎的疗效分析  

ANALYSIS OF THERAPEUTIC EFFECT OF TELBIVUDINE ON SEVERE CHRONIC HEPATITIS B

作　　者：秦荣[1] 朱淑军[1] 王光恺[1] 邓淦林[1] 

机构地区：[1]东莞市太平人民医院,广东东莞523900

出　　处：《现代医院》2012年第5期55-57,共3页Modern Hospitals

摘　　要：目的研究替比夫定治疗慢性乙型重型肝炎的疗效。方法将24例慢性乙型重型肝炎患者随机分为替比夫定组和对照组各12例。两组均给予基础综合治疗;替比夫定组加用替比夫定600 mg/d,口服。疗程为12 w。治疗前后检查肝功能、凝血酶原活动度及HBV-DNA并记录患者症状。结果治疗12 w后,两组患者的临床症状、肝功能、凝血酶原活动度均有所改善,替比夫定组疗效好于对照组,但其有效率与对照组相比差异无统计学意义(p>0.05)。替比夫定组患者TBIL、ALT、AST及PTA较对照组治疗后下降更显著,各项指标之间的差异均有统计学意义(均p<0.05)。替比夫定组治疗后血清HBV-DNA水平与对照组治疗后相比较,两组差异有统计学意义(p=0.015)。结论替比夫定可明显抑制重型乙型肝炎病毒复制,与基础综合治疗措施联合能显著改善慢性乙型重型肝炎患者的临床症状。Objective To investigate the clinical effect of telbivudine therapy on severe chronic hepatitis B. Methods Twenty four patients with severe chronic hepatitis B were randomly divided into two groups. Each group has twelve patients and was given basic comprehensive treatment. Telbivudine group was given the same drugs plus telbivudine （600 mg/d） for 12 w. The major clinical outcomes and hepatic function of two groups were evaluated after twelve weeks of treatment. Results The major clinical symptoms, hepatic function and PTA improved in both group than before treatment. There was obviously decreasing in TBIL,ALT,AST,PTA and the level of HBV - DNA in telbivudine group after 12 weeks, the index of telbivudine group showed a significant difference from the control group （p 〈 0.05）. The serum HBV -DNA level of telbivudine group after treatment comparing with that of control group had significant statistic difference（p = 0. 015）. Conclusion Telbivudine can effectively inhibit HBV replication and telbivudine combined with basic comprehensive treatment can significantly improve the chronic severe hepatitis B patients with clinical symptoms.

关 键 词：慢性乙型重型肝炎 凝血酶原活动度 HBV—DNA 

分 类 号：R512.62[医药卫生—内科学]